Italian medical device maker Sorin Group (BIT:SRN) landed CE Mark approval for Inspire 6, the first model of its new family of adult oxygenators for use in patients during cardiopulmonary bypass procedures.
When used in combination with a heart-lung machine, the oxygenator replaces the function of lungs during cardiac surgery.
”The Inspire family leverages over 30 years of Sorin Group knowledge and development expertise in the cardiopulmonary bypass market", said Sorin Group president Michel Darnaud in prepared remarks.
Sorin plans to start market assessment studies for the Inspire 6 system shortly after the commercial launch in the first half of 2012.
The Italian med-tech maker invested $7 million in Enopace Biomedical in October to fund the development of a neuromodulation system for patients with congestive heart failure.
Enopace’s technology consists of an implantable neurostimulator that increases heart efficiency by reducing the workload placed on the left ventricle. Sorin Group’s $7 million investment will finance clinical studies and ongoing product development.
"Through Enopace Biomedical, Sorin Group will support the development of a unique medical device solution for today’s most urgent, unmet clinical need. This segment represents one of the largest and fast-growing market opportunities in the medical device field" said Sorin Group CEO André-Michel Ballester in prepared remarks.